Measuring Tumor Epichaperome Expression Using [124I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer For ...
Notice that the best design was found in three tries out of ten. It may be a good idea to repeat the search with more tries (see the ITER= option.) You can use the ALIASING option of the GLM procedure ...
The FDA and Corbus Pharmaceuticals Holdings, Inc., have agreed on second-line registrational study designs evaluating CRB-701 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results